← All companies

IFRX

InflaRx N.V.

IFRX Nasdaq Pharmaceutical Preparations EDGAR ↗

$1.75

+0.03 +1.74%

Key statistics

from XBRL data in SEC filings

Market cap

$127M

Revenue (TTM)

—

Net income (TTM)

—

EPS (TTM)

—

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

—

Total assets

—

Gross margin

—

52-week range

$0.74 – $2.95

Recent SEC filings

40 most recent

Annual, quarterly & current reports

6-K Jun 30, 2026 6-K May 7, 2026 6-K May 6, 2026 6-K May 6, 2026 6-K May 4, 2026 6-K Apr 28, 2026 6-K Apr 23, 2026 6-K REPORT OF FOREIGN PRIVATE ISSUER Apr 9, 2026 6-K Apr 2, 2026 20-F ANNUAL REPORT Mar 20, 2026 6-K REPORT OF FOREIGN PRIVATE ISSUER Mar 19, 2026 6-K Mar 16, 2026 6-K Jan 8, 2026 6-K Dec 30, 2025 6-K Nov 10, 2025 6-K Nov 10, 2025 6-K Sep 12, 2025 6-K REPORT OF FOREIGN PRIVATE ISSUER Aug 7, 2025 6-K Jul 14, 2025 6-K Jun 27, 2025 6-K May 28, 2025 6-K May 7, 2025 6-K Apr 24, 2025 6-K Apr 3, 2025 20-F ANNUAL REPORT Mar 20, 2025 6-K Mar 20, 2025 6-K FORM 6-K Feb 18, 2025 6-K Jan 15, 2025 6-K Dec 20, 2024 6-K Nov 15, 2024 6-K Nov 8, 2024 6-K REPORT OF FOREIGN PRIVATE ISSUER Aug 8, 2024 6-K Jun 28, 2024 6-K 6K Jun 24, 2024 6-K Jun 5, 2024 6-K REPORT OF FOREIGN PRIVATE ISSUER May 21, 2024 6-K REPORT OF FOREIGN PRIVATE ISSUER May 8, 2024 6-K REPORT OF FOREIGN PRIVATE ISSUER Apr 25, 2024 6-K 6K Apr 4, 2024 6-K Mar 21, 2024